{"id":"dupilumab-injectable-product","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Injection site reactions"},{"rate":"10-15","effect":"Conjunctivitis"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Oropharyngeal pain"},{"rate":"5-10","effect":"Upper respiratory tract infection"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dupilumab binds to IL-4 receptor alpha, a shared component of IL-4 and IL-13 signaling pathways that drive type 2 inflammation. By blocking this receptor, it suppresses the production of IgE and inflammatory cytokines, reducing eosinophil recruitment and activation. This mechanism addresses the underlying pathophysiology of multiple type 2 inflammatory conditions including atopic dermatitis, asthma, and eosinophilic diseases.","oneSentence":"Dupilumab is a monoclonal antibody that blocks the IL-4 receptor alpha subunit, inhibiting signaling of interleukin-4 and interleukin-13 to reduce type 2 inflammatory responses.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:35:47.950Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate-to-severe atopic dermatitis"},{"name":"Moderate-to-severe asthma with type 2 inflammation"},{"name":"Chronic rhinosinusitis with nasal polyps"},{"name":"Eosinophilic esophagitis"},{"name":"Eosinophilic granulomatosis with polyangiitis"}]},"trialDetails":[{"nctId":"NCT06868212","phase":"PHASE3","title":"A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-07-11","conditions":"Chronic Spontaneous Urticaria (CSU)","enrollment":400},{"nctId":"NCT03694158","phase":"PHASE4","title":"Investigating Dupilumab's Effect in Asthma by Genotype","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boston Children's Hospital","startDate":"2021-09-08","conditions":"Asthma","enrollment":150},{"nctId":"NCT05964465","phase":"PHASE4","title":"Mechanisms of Smell Improvement With Dupilumab.","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2023-08-10","conditions":"Chronic Rhinosinusitis With Nasal Polyps","enrollment":60},{"nctId":"NCT05347771","phase":"PHASE2","title":"Prevention of Asthma Exacerbations Using Dupilumab in Urban Children and Adolescents","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2022-05-04","conditions":"Asthma","enrollment":240},{"nctId":"NCT06116526","phase":"PHASE4","title":"Dupilumab De-escalation in Pediatric Atopic Dermatitis","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2024-04-01","conditions":"Atopic Dermatitis","enrollment":30},{"nctId":"NCT07091175","phase":"PHASE2","title":"Dupilumab Therapy in Nephrotic Syndrome in Children","status":"RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2025-11-27","conditions":"Nephrotic Syndrome in Children, Nephrotic Syndrome Steroid-Dependent","enrollment":66},{"nctId":"NCT07257835","phase":"","title":"Dupilumab Therapy for EGIDs","status":"RECRUITING","sponsor":"Children's Hospital of Fudan University","startDate":"2025-01-01","conditions":"Eosinophilic Gastrointestinal Disorders (EGIDs)","enrollment":20},{"nctId":"NCT04256759","phase":"PHASE2","title":"Dupilumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2020-09-01","conditions":"Pruritus","enrollment":9},{"nctId":"NCT04743791","phase":"PHASE4","title":"Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma","status":"RECRUITING","sponsor":"Sally E. Wenzel MD","startDate":"2022-10-17","conditions":"Asthma","enrollment":30},{"nctId":"NCT03678545","phase":"PHASE2","title":"Dupilumab in Eosinophilic Gastritis","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2021-05-15","conditions":"Eosinophilic Gastritis, Eosinophilic Gastroenteritis","enrollment":41},{"nctId":"NCT05976386","phase":"PHASE1","title":"Single Dose Comparability Study of New and Current Dupilumab Drug Products Subcutaneously Administered in Healthy Adults","status":"COMPLETED","sponsor":"Sanofi","startDate":"2021-06-08","conditions":"Healthy Volunteers","enrollment":182},{"nctId":"NCT07021495","phase":"","title":"SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2025-07-29","conditions":"Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS), Psoriasis (PsO)","enrollment":840},{"nctId":"NCT06087627","phase":"","title":"A Non-interventional Study to Describe the Dupilumab Long-term Treatment, Safety and Patient Reported Outcomes in Chronic Nodular Prurigo (Prurigo Nodularis) in Clinical Routine","status":"RECRUITING","sponsor":"Sanofi","startDate":"2023-12-27","conditions":"Prurigo Nodularis","enrollment":150},{"nctId":"NCT04380038","phase":"PHASE4","title":"Viral Infection in Asthma (VIA) Study","status":"RECRUITING","sponsor":"University of Virginia","startDate":"2022-05-01","conditions":"Asthma","enrollment":60},{"nctId":"NCT04596189","phase":"PHASE4","title":"Dupilumab for Prevention of Recurrence of CRSwNP After ESS","status":"COMPLETED","sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","startDate":"2021-05-25","conditions":"Chronic Rhinosinusitis With Nasal Polyps","enrollment":30},{"nctId":"NCT04200755","phase":"PHASE2","title":"Clinical Trial to Evaluate Efficacy and Safety of Dupilumab in Localized Scleroderma","status":"COMPLETED","sponsor":"University of Cologne","startDate":"2020-05-19","conditions":"Localized Scleroderma","enrollment":45},{"nctId":"NCT05042258","phase":"PHASE4","title":"Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis","status":"RECRUITING","sponsor":"Northwestern University","startDate":"2024-08-12","conditions":"Atopic Dermatitis, Sleep Disturbance","enrollment":40},{"nctId":"NCT06192563","phase":"","title":"A Study to Observe How Adolescent Patients With Severe Atopic Dermatitis Despite Less Extensive Skin Lesions (Eczema Area and Severity Index Score < 16) Respond to Dupilumab Treatment","status":"RECRUITING","sponsor":"Sanofi","startDate":"2023-11-30","conditions":"Dermatitis Atopic","enrollment":150},{"nctId":"NCT05976360","phase":"PHASE1","title":"A Study to Investigate the Pharmacokinetics, Tolerability and Safety of Two Different Dupilumab Drug Products in Healthy Participants","status":"COMPLETED","sponsor":"Sanofi","startDate":"2014-11-02","conditions":"Healthy Volunteer","enrollment":38},{"nctId":"NCT05976373","phase":"PHASE1","title":"A Study to Investigate the Pharmacokinetics (PK), Tolerability and Safety of Two Different Dupilumab Drug Products in Healthy Participants.","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-01-05","conditions":"Healthy Volunteers","enrollment":38},{"nctId":"NCT03675022","phase":"EARLY_PHASE1","title":"Effect of Dupilumab on Sleep Apnea in Patients With Rhinosinusitis","status":"TERMINATED","sponsor":"Brigham and Women's Hospital","startDate":"2018-08-15","conditions":"Sleep Apnea, Rhinosinusitis Chronic","enrollment":9},{"nctId":"NCT03387852","phase":"PHASE2","title":"Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Participants","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-03-12","conditions":"Asthma","enrollment":296},{"nctId":"NCT02573233","phase":"PHASE2","title":"Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-01-27","conditions":"Asthma","enrollment":42},{"nctId":"NCT03720470","phase":"PHASE3","title":"Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-10-29","conditions":"Dermatitis, Dermatitis, Atopic, Eczema","enrollment":838},{"nctId":"NCT04520308","phase":"PHASE4","title":"An Open-label, Single-arm Longitudinal Study With Dupilumab for Patients With Atopic Dermatitis","status":"UNKNOWN","sponsor":"Eric Simpson","startDate":"2020-09-01","conditions":"Atopic Dermatitis, AD, Eczema","enrollment":45},{"nctId":"NCT01537640","phase":"PHASE1","title":"Comparison of the Pharmacokinetics and Safety of Two SAR231893 (REGN668) Drug Products in Healthy Subjects","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-02","conditions":"Healthy","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Rhinovirus"],"phase":"marketed","status":"active","brandName":"Dupilumab Injectable Product","genericName":"Dupilumab Injectable Product","companyName":"University of Virginia","companyId":"university-of-virginia","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dupilumab is a monoclonal antibody that blocks the IL-4 receptor alpha subunit, inhibiting signaling of interleukin-4 and interleukin-13 to reduce type 2 inflammatory responses. Used for Moderate-to-severe atopic dermatitis, Moderate-to-severe asthma with type 2 inflammation, Chronic rhinosinusitis with nasal polyps.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}